DK3403669T3 - Fremgangsmåder til behandling og forebyggelse af staphylococcus aureus-infektioner og forbundne tilstande - Google Patents

Fremgangsmåder til behandling og forebyggelse af staphylococcus aureus-infektioner og forbundne tilstande Download PDF

Info

Publication number
DK3403669T3
DK3403669T3 DK18182774.2T DK18182774T DK3403669T3 DK 3403669 T3 DK3403669 T3 DK 3403669T3 DK 18182774 T DK18182774 T DK 18182774T DK 3403669 T3 DK3403669 T3 DK 3403669T3
Authority
DK
Denmark
Prior art keywords
procedures
prevention
treatment
staphylococcus aureus
associated conditions
Prior art date
Application number
DK18182774.2T
Other languages
Danish (da)
English (en)
Inventor
Iii Francis Alonzo
Victor J Torres
Original Assignee
Univ New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York filed Critical Univ New York
Application granted granted Critical
Publication of DK3403669T3 publication Critical patent/DK3403669T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56938—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/305—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F)
    • G01N2333/31—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
DK18182774.2T 2011-06-19 2012-06-19 Fremgangsmåder til behandling og forebyggelse af staphylococcus aureus-infektioner og forbundne tilstande DK3403669T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161498596P 2011-06-19 2011-06-19
EP12801920.5A EP2720714B1 (en) 2011-06-19 2012-06-19 Methods of treating and preventing staphylococcus aureus infections and associated conditions

Publications (1)

Publication Number Publication Date
DK3403669T3 true DK3403669T3 (da) 2020-08-24

Family

ID=47423177

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18182774.2T DK3403669T3 (da) 2011-06-19 2012-06-19 Fremgangsmåder til behandling og forebyggelse af staphylococcus aureus-infektioner og forbundne tilstande

Country Status (20)

Country Link
US (7) US9091689B2 (enExample)
EP (3) EP3777885A1 (enExample)
JP (4) JP6170913B2 (enExample)
KR (1) KR102050267B1 (enExample)
CN (3) CN103717234A (enExample)
AU (1) AU2012273123C1 (enExample)
BR (2) BR122020000047B1 (enExample)
CA (1) CA2839554C (enExample)
CL (2) CL2013003650A1 (enExample)
DK (1) DK3403669T3 (enExample)
ES (2) ES2812181T3 (enExample)
HR (1) HRP20201265T1 (enExample)
HU (1) HUE051832T2 (enExample)
IL (2) IL229922B (enExample)
LT (1) LT3403669T (enExample)
MX (2) MX340446B (enExample)
NZ (1) NZ764564A (enExample)
RU (1) RU2635462C2 (enExample)
SI (1) SI3403669T1 (enExample)
WO (1) WO2012177658A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103717234A (zh) 2011-06-19 2014-04-09 纽约大学 治疗和预防金黄色葡萄球菌感染及相关病状的方法
US9657103B2 (en) 2012-05-02 2017-05-23 New York University Methods of treating and preventing Staphylococcus aureus infections and associated conditions
EP3441474B1 (en) * 2013-06-18 2020-07-22 New York University Pharmaceutical compositions containing a mutated leukocidin e
RU2016119052A3 (en) * 2013-10-17 2018-09-10 Arsanis Biosciences Gmbh Cross-reactive Staphylococcus aureus antibody sequences
WO2015089073A2 (en) * 2013-12-09 2015-06-18 New York University Compositions and methods for phagocyte delivery of anti-staphylococcal agents
BE1022875B1 (fr) * 2014-03-26 2016-09-30 Glaxosmithkline Biologicals S.A. Compositions pour une immunisation contre staphylococcus aureus
CA2956429A1 (en) * 2014-08-12 2016-02-18 Arsanis Biosciences Gmbh Predicting s. aureus disease
US20180179267A1 (en) * 2015-04-17 2018-06-28 Arsanis Biosciences Gmbh Anti-staphylococcus aureus antibody combination preparation
EP3302532A4 (en) * 2015-06-05 2019-01-09 New York University COMPOSITIONS AND METHODS FOR BIOLOGICAL ACTIVE AGGREGATES AGAINST STAPHYLOKOKEN
CN105641689B (zh) * 2016-01-21 2024-09-10 浙江海隆生物科技股份有限公司 一种奶牛金黄色葡萄球菌β-溶血素亚单位疫苗的制备方法及应用
US11104724B2 (en) 2016-05-23 2021-08-31 New York University Compositions and methods for antibodies targeting staphylococcal leukotoxins
US11324815B2 (en) 2016-10-21 2022-05-10 Socpra—Sciences et Genie, S.E.C. Vaccine constructs and uses thereof against Staphylococcus infections
JP7211626B2 (ja) * 2017-02-20 2023-01-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 無症候性脳虚血に関する血清学的アッセイ
CN107224575B (zh) * 2017-03-06 2018-11-09 浙江海隆生物科技有限公司 奶牛金黄色葡萄球菌乳房炎亚单位疫苗的组合物及其制备方法和应用
CN106749652A (zh) * 2017-03-14 2017-05-31 天津喜诺生物医药有限公司 一种金黄色葡萄球菌肽聚糖的多克隆抗体
EP3720458A4 (en) 2017-12-05 2021-12-08 BioPlx, Inc. METHODS AND COMPOSITIONS FOR PREVENTING MICROBIAL INFECTION
BR112021001214A2 (pt) 2018-07-24 2021-04-27 Medimmune, Llc anticorpo dirigido contra o fator de aglutinação a (clfa) de s. aureus
BR112021016996A8 (pt) * 2019-02-28 2022-11-22 Dandi Bioscience Inc Polipeptídeo com atividade antibacteriana, composição para prevenir ou tratar sepsis compreendendo a mesma e composição antibacteriana
CN111423516B (zh) * 2020-04-01 2022-02-11 广州佰斯伦医疗器械有限公司 一种蛋白及其在创口修复及抑菌中的应用
CN111398194B (zh) * 2020-04-10 2020-11-03 上海华茂药业有限公司 一种用于测定艾考糊精中肽聚糖的方法
CN112851770B (zh) * 2021-02-05 2022-10-04 中国人民解放军陆军军医大学 一种用于诊断或防治金黄色葡萄球菌感染的α溶血素抗原表位肽及其应用
CN114317787A (zh) * 2021-12-29 2022-04-12 成都大学 吸附磁珠及其试剂盒和用途以及检测金黄色葡萄球菌的方法
CN115991766B (zh) * 2023-03-13 2025-01-14 广州庆毅生物医药科技有限公司 一种细菌抗原检测试剂盒及其应用
CN119431528B (zh) * 2024-10-28 2025-10-14 中国人民解放军陆军军医大学 一种金黄色葡萄球菌毒素LukG抗原表位肽及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1121135B1 (en) 1998-09-14 2009-01-28 Nabi Biopharmaceuticals Compositions of beta-glucans and specific immunoglobulins
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
AU2002306849A1 (en) 2001-03-21 2002-10-08 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
GB0107661D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
US20030171563A1 (en) 2001-05-18 2003-09-11 Mcnamara Peter J. Regulators of bacterial virulence factor expression
US7288654B2 (en) 2003-02-07 2007-10-30 Takeda Pharmaceutical Company Ltd Fused-ring pyridine derivative, process for producing the same, and use
IL157398A0 (en) 2003-08-14 2004-02-19 Hadasit Med Res Service Pharmaceutical compositions comprising ccr5 antagonists
US7622125B2 (en) 2004-05-05 2009-11-24 Novartis Vaccines And Diagnostics, Inc. Polycistronic HIV vector constructs
EP2893938B1 (en) 2004-09-22 2019-03-06 GlaxoSmithKline Biologicals SA Immunogenic composition for use in vaccination against Staphylococcei
WO2007062150A2 (en) 2005-11-25 2007-05-31 University Of Medicine And Dentistry Of New Jersey Leukotoxin compositions and therapeutic methods
EP1986673A2 (en) 2006-02-13 2008-11-05 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health and Human Services Methods and compositions related to ghs-r antagonists
EP2043690A1 (en) * 2006-06-12 2009-04-08 Nabi Biopharmaceuticals Use of alpha-toxin for treating and preventing staphylococcus infections
KR20090013827A (ko) 2006-06-12 2009-02-05 화이자 프로덕츠 인크. Ｈｉｖ 환자에서 면역 재구성을 증진시키고 기회 감염을 치료하기 위한 ｃｃｒ５ 길항제
JP2008013447A (ja) * 2006-07-03 2008-01-24 Juntendo 毒素検出方法
WO2008099278A2 (en) 2007-02-15 2008-08-21 Pfizer Limited Pharmaceutical compositions and methods for ccr5 antagonists
CN102448482A (zh) 2009-03-27 2012-05-09 范安德尔研究所 甲状旁腺素肽和甲状旁腺素相关蛋白肽及使用方法
ES2565377T3 (es) * 2009-04-14 2016-04-04 Glaxosmithkline Biologicals Sa Composiciones para inmunización contra Staphylococcus aureus
US8409584B2 (en) 2009-05-05 2013-04-02 New York University Immunotherapy targeting of the shared abnormal conformational state of amyloidogenic peptides/proteins
EP2488198B1 (en) 2009-10-13 2016-09-28 Rutgers, the State University of New Jersey Treatment and diagnosis of autoimmune disorders
KR20190133290A (ko) * 2010-05-05 2019-12-02 뉴욕 유니버시티 스타필로코커스 아우레우스 류코시딘, 치료 조성물 및 그것의 용도
CN103717234A (zh) * 2011-06-19 2014-04-09 纽约大学 治疗和预防金黄色葡萄球菌感染及相关病状的方法
BR112013032911A2 (pt) * 2011-06-19 2017-01-24 Univ New York leucotoxina e/d como um novo agente anti-inflamatório e microbicida

Also Published As

Publication number Publication date
AU2012273123B2 (en) 2018-01-04
JP6758363B2 (ja) 2020-09-23
US9091689B2 (en) 2015-07-28
EP3777885A1 (en) 2021-02-17
JP6452765B2 (ja) 2019-01-16
IL229922B (en) 2018-05-31
US20130017203A1 (en) 2013-01-17
AU2012273123A1 (en) 2014-01-16
WO2012177658A8 (en) 2014-02-20
US11078258B2 (en) 2021-08-03
NZ764564A (en) 2022-10-28
US10669329B2 (en) 2020-06-02
NZ710439A (en) 2017-04-28
EP2720714B1 (en) 2018-07-18
EP3403669A1 (en) 2018-11-21
ES2812181T3 (es) 2021-03-16
IL258886A (en) 2018-06-28
US20150274814A1 (en) 2015-10-01
RU2635462C2 (ru) 2017-11-13
BR112013032774A2 (pt) 2017-01-31
NZ619938A (en) 2016-03-31
MX2013014640A (es) 2014-05-14
LT3403669T (lt) 2020-10-12
CN103717234A (zh) 2014-04-09
CN104474531A (zh) 2015-04-01
CL2019002056A1 (es) 2019-11-29
BR112013032774B1 (pt) 2020-05-05
US20210340228A1 (en) 2021-11-04
US9481723B2 (en) 2016-11-01
JP7129451B2 (ja) 2022-09-01
EP2720714A4 (en) 2015-01-14
JP2017214397A (ja) 2017-12-07
MX357938B (es) 2018-07-31
EP2720714A2 (en) 2014-04-23
MX340446B (es) 2016-07-08
CL2013003650A1 (es) 2014-09-26
JP6170913B2 (ja) 2017-07-26
EP3403669B1 (en) 2020-07-15
RU2014101488A (ru) 2015-07-27
JP2014520149A (ja) 2014-08-21
US20200392211A1 (en) 2020-12-17
CA2839554A1 (en) 2012-12-27
SI3403669T1 (sl) 2020-11-30
AU2012273123C1 (en) 2018-08-09
US20190135900A1 (en) 2019-05-09
US9783597B2 (en) 2017-10-10
JP2019034976A (ja) 2019-03-07
JP2020193225A (ja) 2020-12-03
BR122020000047B1 (pt) 2021-04-13
KR20140039294A (ko) 2014-04-01
KR102050267B1 (ko) 2019-11-29
US20170008953A1 (en) 2017-01-12
WO2012177658A2 (en) 2012-12-27
CA2839554C (en) 2023-09-26
HRP20201265T1 (hr) 2021-02-19
WO2012177658A3 (en) 2013-02-21
US20180057571A1 (en) 2018-03-01
HUE051832T2 (hu) 2021-03-29
NZ730359A (en) 2020-05-29
US10202440B2 (en) 2019-02-12
CN109893644A (zh) 2019-06-18
ES2684088T3 (es) 2018-10-01

Similar Documents

Publication Publication Date Title
DK3403669T3 (da) Fremgangsmåder til behandling og forebyggelse af staphylococcus aureus-infektioner og forbundne tilstande
DK3251678T3 (da) Benzoxaborolderivater til behandling af bakterieinfektioner
DK2852391T3 (da) Systemer til behandling af lungeinfektioner
DK3785717T3 (da) Fremgangsmåder til behandling af coronaviridae-infektioner
DK2833899T3 (da) Sammensætninger, der omfatter cocktails af antibakterielle fager, og anvendelser deraf til behandling af bakterieinfektioner
DK3511328T3 (da) Organiske monobactam-forbindelser til behandling af bakterieinfektioner
DK3466432T3 (da) Fremgangsmåder til behandling af pulmonale non-tuberkuløse mykobakterielle infektioner
BR112015002524A2 (pt) derivados de alquilpirimidina para o tratamento de infecções virais e outras doenças.
DK3520805T3 (da) Sammensætninger til behandling af myelofibrose
DK2903967T6 (da) Acylaminopyrimidinderivater til behandling af virusinfektioner og andre sygdomme
DK3444268T3 (da) Staphylococcus aureus-leukocidiner, terapeutiske sammensætninger og anvendelser deraf
SG10201703965SA (en) Compositions and methods for treating and preventing staphylococcus aureus infections
DK3238707T3 (da) Sammensætninger og fremgangsmåder til behandling af intestinal hyperpermeabilitet
DK2818241T3 (da) Fremgangsmåde til fremstilling af behandlingsapparat udstyret med katalysatorbærende honeycombstruktur
DK2861214T3 (da) Tilpassede liposomer til behandling af bakterieinfektioner
DK3016493T3 (da) Behandling til desinficering af frø
DK3200748T3 (da) Sammensætninger og fremgangsmåder til behandling og profylakse af infektioner på operationssted
AP2015008338A0 (en) Compounds for the treatment and prevention of retroviral infections
EP3366299A4 (en) MEANS OF PREVENTING INFECTIONS FOR SMALL CHILDREN
DK2900259T3 (da) Glycosidase-regime til behandling af infektionssygdomme
DK2892556T3 (da) Sammensætninger og fremgangsmåder til behandling af sygdomme
IL235284A0 (en) Methods for the treatment and prevention of Staphylococcus aureus infections and related conditions
DK2825636T3 (da) Behandling af sædceller
IL241249A0 (en) Antisense molecules for the treatment of Staphylococcus aureus infection
IL241226A0 (en) Antisense molecules for the treatment of Staphylococcus aureus infection